SCHEMBL6987464

SCHEMBL6987464

CSc1nccc(-c2[nH]cnc2-c2ccccc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
CYP3A4 P08684 1/20 0.54
MAPT P10636 1/20 0.54
MAPK14 Q16539 7/20 0.49
MAPK13 O15264 3/20 0.49
MAPK12 P53778 3/20 0.49
MAPK11 Q15759 3/20 0.49
CSNK1E P49674 1/20 0.49
CSNK1D P48730 2/20 0.46
JAK3 P52333 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
IDO1 P14902 3/20 0.41
RAF1 P04049 2/20 0.41
MAPK9 P45984 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7670525 0.86 MAPK14 (0.62) MAPTMAPK14MAPK13MAPK12MAPK11
SCHEMBL1034731 0.80 DUSP10 (0.54) KDM4EMAPTMAPK14MAPK13MAPK12
SCHEMBL6070097 0.75 TGFBR1 (0.60) KDM4EMAPK14MAPK13MAPK12MAPK11
SCHEMBL4974887 0.75 MAPK14 (0.81) MAPK14MAPK13MAPK12MAPK11CSNK1D
SCHEMBL5089273 0.74 LMNA (0.45) KDM4EMAPTMAPK14MAPK13MAPK12
SCHEMBL8131381 0.73 MAPK14 (0.57) KDM4EMAPK14MAPK13MAPK12MAPK11
SCHEMBL6132086 0.73 TGFBR1 (0.50) KDM4EMAPK14MAPK13MAPK12MAPK11
SCHEMBL6260027 0.73 KDM4E (0.52) KDM4EMAPTMAPK14MAPK13MAPK12
SCHEMBL13038810 0.73 KDM4E (0.61) KDM4ECYP3A4MAPTMAPK14MAPK13
SCHEMBL224770 0.72 KDM4E (1.00) KDM4ECYP3A4MAPTMAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224180-B1 SUBSTITUTED AZOLES NOVARTIS AG (CH) 2003-07-02 EP disclosed
US-6579874-B2 P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives NOVARTIS AG (CH) 2003-06-17 US disclosed
US-20020049220-A1 Substituted azoles NOVARTIS AG (CH) 2002-04-25 US disclosed
WO-2000026209-A1 ANTI-INFLAMMATORY 4-PHENYL-5-PYRIMIDINYL-IMIDAZOLES NOVARTIS AG (CH) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049220-A1 Substituted azoles MAPK1, MAPK4, MAP3K1 KDM4E 1625/4885CYP3A4 1098/4885MAPT 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.